MORRIS PLAINS, N.J., Nov. 30, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that nine presentations involving its product candidates will be given at the 51st American Society of Hematology (ASH) Annual Meeting, scheduled for December 5 - 8, 2009, in New Orleans, LA. The schedule and meeting places for the presentations, together with the publication and board numbers are listed below:
* "Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP)" (Publication No. 1322, Poster Session: Disorders of Platelet Number of Function Poster I, Saturday, December 5, 5:30 p.m. - 7:30 p.m., Poster Board I-344, Ernest N. Morial Convention Center, Hall E) * "Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death that is Dependent on Actin Polymerization and Inhibition of NF-kB" Publication No. 1694, Poster Session: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster I, Saturday, December 5, 5:30 p.m. - 7:30 p.m., Poster Board I- 716, Ernest N. Morial Convention Center, Hall E) * "First Bispecific Antibody Immunocytokine (Anti-CD20/HLA-DR- Interferon-a2b) is Highly Toxic for Human Lymphoma Cells in Vitro" (Publication No. 1695, Poster Session: Lymphoma: Pre- Clinical - Chemotherapy and Biologic Agents Poster I, Saturday, December 5, 5:30 p.m. - 7:30 p.m., Poster Board I-717, Ernest N. Morial Convention Center, Hall E) * "PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma" (Publication No. 137, Oral Session: Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Clinicopathological Correlations in Non-Hodgkin's Lymphoma, Sunday, December 6, 5:30 p.m., Ernest N. Morial Convention Center, E-1) * "Differential Effects of Milatuzumab on Human Antigen-Presenting Cells in Comparison to Malignant B Cells" (Publication No. 2744, Poster Session: Molecular Pharmacology, Drug Resistance Poster II, Sunday, December 6, 6:00 p.m. - 8:00 p.m., Poster Board II- 720, Ernest N. Morial Convention Center, Hall E) * "Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor on the Surface of B Cells" (Publication No. 721, Oral Session: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Novel Antibody-Based Therapeutics for Lymphomas, Monday, December 7, 4:30 p.m., Ernest N. Morial Convention Center, 243-245) * "A Novel Ribonuclease-Based Immunotoxin Comprising Quadruple Ranpirnase (Rap) Site-Specifically Conjugated to an Anti-CD22 IgG Showing Potent Anti-Lymphoma Activity" (Publication No. 3721, Poster Session: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster III, Monday, December 7, 6:00 p.m. - 8:00 p.m., Poster Board III-657, Ernest N. Morial Convention Center, Hall E) * "Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, is Mediated Through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways" (Publication No. 3738, Poster Session: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster III, Monday, December 7, 6:00 p.m. - 8:00 p.m., Poster Board III-674, Ernest N. Morial Convention Center, Hall E) * "Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies" (Publication No. 3757, Poster Session: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster III, Monday, December 7, 6:00 p.m. - 8:00 p.m., Poster Board III-693, Ernest N. Morial Convention Center, Hall E)
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 141 patents issued in the United States and more than 300 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.